Want to see AGEN full AI Analyst Report?

Agenus (AGEN) Earnings Dates, Call Summary & Reports

2,046 Followers

Earnings Data

Report Date

Aug 11, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

0.05

Last Year’s EPS

-1

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q1 2025

Earnings Call Date:May 12, 2025|

% Change Since:

Earnings Call Sentiment|Neutral

The earnings call highlighted several positive developments, including strategic hires, promising BOT/BAL data, and multiple capital proposals which could strengthen the company's financial position. However, financial metrics such as a decreased cash balance and lower revenue compared to the previous year, alongside ongoing regulatory challenges, present notable challenges. The overall sentiment is cautiously optimistic as the highlights and lowlights are balanced.

Company Guidance

During Agenus Inc.'s First Quarter 2025 Earnings Conference Call, the company outlined several strategic priorities, focusing on their innovative BOT/BAL data, operational efficiencies, and impending transactions to enhance financial strength. They aim to reduce operational cash burn to below $50 million annually by the second half of 2025. The company's financials for the first quarter showcased a cash balance of $18.5 million, a reduction from $40.4 million at the end of 2024, with a net loss of $26.4 million or $1.03 per share. Revenue was reported at $24.1 million, primarily from non-cash royalty revenue. Agenus has received four transaction proposals, including a potential Emeryville facility sale and two BOT/BAL licensing deals, aimed to bolster their balance sheet. The call emphasized the wide-reaching potential of BOT/BAL in treating cold tumors, with promising data from recent studies, and discussed the evolving regulatory landscape that could expedite therapy approvals.

Operational Efficiency Goals

Agenus is on track to reduce its operational cash burn to below $50 million annualized in the second half of 2025.

New Leadership and Strategic Hire

Dr. Richard Goldberg, a GI-Oncology expert, joined as Chief Development Officer to advance regulatory filings in metastatic colorectal cancer and other tumor types.

Promising BOT/BAL Data

New BOT/BAL data shows durable responses in cold tumors, including MSS colorectal cancer, with deep and durable disease control demonstrated in heavily pre-treated liver cancer patients.

Strategic Capital Proposals

Agenus received four formal transaction proposals, including the sale of the Emeryville facility, a significant equity investment at a premium, and two licensing deals for BOT/BAL.

Regulatory Environment Shift

Changes in FDA policies may favor rapid approval of transformative therapies, aligning with Agenus' goals for BOT/BAL's accelerated approval.

Agenus (AGEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AGEN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Play Transcript
Aug 11, 2026	2026 (Q2)	0.05 / -	-1	―	―
May 11, 2026	2026 (Q1)	2.10 / 1.02	-1.03	199.03% (+2.05)	―
Mar 16, 2026	2025 (Q4)	-1.04 / -0.30	-2.04	85.29% (+1.74)	―
Nov 10, 2025	2025 (Q3)	2.20 / 1.94	-3.08	162.99% (+5.02)	―
Aug 11, 2025	2025 (Q2)	2.42 / -1.00	-2.52	60.32% (+1.52)
May 12, 2025	2025 (Q1)	-1.65 / -1.03	-3.04	66.12% (+2.01)
Mar 11, 2025	2024 (Q4)	-2.54 / -2.04	-2.6	21.54% (+0.56)
Nov 12, 2024	2024 (Q3)	-2.31 / -3.08	-3.2	3.75% (+0.12)
Aug 08, 2024	2024 (Q2)	-1.07 / -2.52	-4	37.00% (+1.48)
May 07, 2024	2024 (Q1)	-3.21 / -3.04	-4.4	30.91% (+1.36)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AGEN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 11, 2026	$3.82	$3.26	-14.66%
Mar 16, 2026	$3.10	$3.29	+6.13%
Nov 10, 2025	$3.98	$4.21	+5.78%
Aug 11, 2025	$4.80	$4.27	-11.04%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Agenus Inc. (AGEN) report earnings?

Agenus Inc. (AGEN) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).

What is Agenus Inc. (AGEN) earnings time?

Agenus Inc. (AGEN) earnings time is at Aug 11, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AGEN EPS forecast?

AGEN EPS forecast for the fiscal quarter 2026 (Q2) is 0.05.